Falsely normal C4 in a case of acquired C1 esterase inhibitor deficiency by McLean-Tooke A et al.
Falsely normal C4 in C1 esterase inhibitor deficiency
Falsely normal C4 in a case of acquired C1 esterase inhibitor
deficiency
Andrew McLean-Tooke, Catherine Stroud, Anne Sampson, Gavin Spickett
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
J Clin Pathol 2007;60:565–566. doi: 10.1136/jcp.2006.041350
A 59-year-old lady presented with recurrent angioedema
without urticaria. The clinical history and examination were
consistent with an acquired C1 esterase deficiency secondary to
lymphoproliferative disease. Despite a low C1 esterase level,
the C4 level assayed by nephelometry on our automated
analyser was normal. Analysis using different nephelometric
analysers revealed consistently low C4, despite consistent
normal readings in our analyser. Further investigation revealed
an IgM-k paraprotein that seemed to interfere with both this
and haematology coagulation assays. Splenic marginal zone
lymphoma was confirmed on bone marrow biopsy.
Monoclonal paraproteins may interfere with nephelometric,
turbidimetric and immunological assays in a non-antibody-
specific manner and should be considered when there are
unusual or unexpected results, particularly in a patient with
lymphoproliferative disease.
A
59-year-old woman was referred with a 13-month history
of recurrent angioedema. These attacks came on over a few
hours, resolved over 2–3 days and occurred approximately
every 2 weeks. Attacks predominantly involved the peripheries
and were not associated with urticaria. There were no identifiable
triggers. She denied any abdominal pain or vomiting. On systemic
enquiry she described fatigue, weight loss, drenching night
sweats, bruising, tinnitus and paraesthesia of her hands,
worsening over this 13-month period. She had no significant
medical history and was not taking any dugs associated with
angioedema. Initial investigations at the district general hospital
showed a microcytic anaemia and a markedly increased
erythrocyte sedimentation rate (136 mm/h). Previous C3 and
C4 levels performed during an episode of angioedema in our
laboratory on an Array 360 analyser (Beckman Coulter, High
Wycombe, UK) were normal (table 1). A C1 esterase level
performed at a different laboratory on a Mira analyser (Roche
Diagnostics, Welwyn Garden City, UK) using a turbidimetric
method was low, and a C4 level at the same laboratory performed
on a BN2 analyser (Dade Behring, Marburg, Germany) was
markedly low, and the patient was referred for assessment.
In the clinic she was pale, with a tachycardia at 130 beats/
min with normal heart sounds. On respiratory examination
sparse crepitations were audible at both bases. Abdominal
examination revealed splenomegaly extending towards the
umbilicus. There was no hepatomegaly or ascites. There was no
evidence of cervical, inguinal or axillary lymphadenopathy.
Further investigations confirmed a microcytic anaemia with a
haemoglobin concentration of 7.2 g/dl. Erythrocyte sedimenta-
tion rate remained increased at 130 mm/h with a C reactive
protein level of 52 mg/l. Liver and renal function were normal
but her lactate dehydrogenase was increased at 354 U/l (normal
range 0–215 U/l). Her prothrombin time was 20 s, which
corrected to 13 s on 50:50 mix with normal plasma. The
activated partial thromboplastin time was markedly prolonged
at 66 s, which only corrected to 59 s on 50:50 mix. Anti-
cardiolipin (aCL) IgG and IgM tests were performed using
commercial antibody kits (Orgentec, Mainz, Germany). aCL IgM
antibody was positive, but levels were untitratable despite serial
dilutions (.1:1600). The aCL IgG antibodies were increased at
26.8 (normal,10). The dilute Russel viper venom time ratio was
increased at 2.0 (normal 0.9–1.2). Autoantibody screen was
antinuclear antibody negative with an increased double-stranded
(ds)-DNA antibody of 87 IU/ml (normal ,20 IU/ml), anti-
smooth muscle antibody titre of 1:320 and weakly positive
antibodies to soluble liver antigens. IgG level was normal with a
mildly increased IgA level (4.28 g/l), and serum electrophoresis
identified a c band. Initial immunofixation showed non-specific
staining, but following treatment of the sample with 2-
mercaptoethanol an IgM k paraprotein at a concentration of
6.6 g/l was identified. Cryoglobulin activity was negative.
Rheumatoid factor activity could not be assayed owing to non-
specific agglutination on the latex agglutination test.
Immunophenotyping by flow cytometry of peripheral blood
revealed a clonal B cell population suggestive of a non-Hodgkin’s
lymphoma and a trephine bone marrow biopsy confirmed splenic
marginal zone lymphoma. A C1 esterase test performed by radial
immunodiffusion using a commercial kit (Binding Site) was low.
Repeat testing of the C4 on the Array 360 remained within the
normal range, but when performed using a BN2 analyser in our
laboratory, the C4 was low. Functional C1 esterase activity was
also low at 15% (normal range 70–120%). IgM depletion
performed by anti-IgM antibody precipitation as previously
described1 showed a dose-dependent correction in C4 levels.
Analysis of IgM-depleted serum confirmed the presence of IgG
anti-smooth muscle antibody, weak positive soluble liver anti-
gens and positive ds-DNA of 42 IU/ml. The artefactually
increased C4 results on the Beckman Array were believed to be
due to paraprotein interference. The patient started receiving
treatment with tranexamic acid, prednisolone and chlorambucil.
Her C1 esterase levels increased (table 1), and she has not had
any further attacks of angioedema.
DISCUSSION
Serum C4 levels are considered to be a highly sensitive and specific
screen for untreated C1 esterase inhibitor deficiency. In the
absence of low C4, it is usually considered not necessary to
proceed to analysis of C1 esterase levels or function.2 3 Acquired C1
esterase inhibitor deficiency usually manifests in two forms: one
associated with lymphoproliferative disease, which is typically low
grade (low-grade lymphoma, chronic lymphocytic leukaemia or
monoclonal gammopathy of uncertain significance), and less
commonly autoimmune diseases, with autoantibodies directed
against the C1 esterase inhibitor molecule.4 Monoclonal para-
proteins have been shown to interfere with several automated
assays of different methodologies, including nephelometry,
turbidimetry and immunological assays via the formation of
precipitates, non-specific antibody binding, hyperviscosity, cryo-
globulinaemia and gel formation.5–7 The phenomenon does not
depend on the antibody specificity of the paraprotein but on
peculiarities of their physiochemical properties.8 Although both
Abbreviation: aCL, anti-cardiolipin
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the Beckman Array and the BN2 analyser use a nephelometric
method, the BN2 analyser seems to be unaffected by the
paraprotein, possibly owing to differences in buffers or the anti-
C4 antibodies used in these assays. Both analysers used a rabbit
anti-human C4 antibody, making heterophilic activity an unlikely
cause for the interference. A positive ds-DNA with negative ANA
is unusual. Multiple autoantibodies have been described pre-
viously in splenic marginal zone lymphoma, independent of the
paraprotein.9 The paraprotein does seem to interfere with the aCL
assay. In a study of patients with monoclonal gammopathies, all
sera of patients with IgA paraproteins were positive for IgA aCL
activity.10 Although less common in IgM and IgG paraproteins,
interferences on aCL ELISAs have also been reported.10–13 In these
patients, the factor detected by ELISA should not be interpreted as
a specific aCL antibody as it may represent non-specific
phospholipid binding by the paraprotein. In patients with unusual
results or those discordant with the clinical picture, especially in
patients with known or suspected lymphoproliferative disease,
interference from a paraprotein should be considered.
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Table 1 Results of C4 and C1 esterase levels
15.05.04 09.08.04 09.11.04 01.02.05
24 weeks prior to
assessment
12 weeks prior to
assessment Results on assessment 8 weeks of treatment
C4* 0.22 0.32 0.47 0.49
C4 ,0.04 0.08 0.07
C1 esterase ,0.06` 0.061 0.11
*C4 levels (normal range 0.18–0.60 g/l) were performed on an Array 360 Nephelometer (Beckman Coulter).
C4 levels (normal range 0.18–0.60 g/l) were performed on a BN2 analyser (Dade Behring).
`C1 esterase levels (normal range 0.18–0.54 g/l) were performed on a Mira turbidometer (Roche).
1C1 esterase levels (normal range 0.18–0.54 g/l) were performed by radial immunodiffusion (Binding Site,
Birmingham, UK).
Take-home messages
N Monoclonal paraproteins may interfere with immunolo-
gical assays.
N This interference may be non-specific and not related to
the antibody specificity of the paraprotein.
N Monoclonal antibodies should be suspected if there are
unusual or unexpected results for the clinical picture,
particularly in patients with lymphoproliferative disease.
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